Lu Yan Pharmaceuticals (002788.SZ) released its performance report for the first half of the year, with a net profit attributable to the parent company of 155 million yuan, a decrease of 18.83%.

The Zhitong Finance APP reports that Lu Yan Medicine (002788.SZ) has released its semi-annual report for 2025. The company's operating income was 10.4 billion yuan, a year-on-year increase of 0.91%. The net profit attributable to the shareholders of the listed company was 155 million yuan, a year-on-year decrease of 18.83%. The net profit attributable to the shareholders of the listed company, excluding non-recurring gains and losses, was 153 million yuan, a year-on-year decrease of 17.93%. The basic earnings per share was 0.4 yuan.